TRDA · NASDAQ
Entrada Therapeutics (TRDA) Stock Price & Fundamentals
Entrada Therapeutics (TRDA) closed at $676.16 on Oct 9, 2026, down 0.59% from the previous close of $680.14.
Share price, past year
1Y +5.69%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $676.16 |
| Sep 30, 2026 | $688.87 |
| Aug 31, 2026 | $659.05 |
| Jul 31, 2026 | $643.96 |
| Jun 30, 2026 | $629.47 |
| May 29, 2026 | $629.72 |
| Apr 30, 2026 | $597.89 |
| Mar 31, 2026 | $567.06 |
| Feb 27, 2026 | $603.42 |
| Jan 30, 2026 | $590.70 |
| Dec 31, 2025 | $597.92 |
| Nov 28, 2025 | $654.27 |
| Oct 31, 2025 | $638.09 |
Key statistics
- Market cap
- $26.33B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.97
- Revenue (TTM)
- $4.69M
- Net income (TTM)
- −$165.78M
- Shares outstanding
- 38.9M
- Dividend yield
- —
- 52-week range
- $557.38 – $695.21
Entrada Therapeutics's market cap is $26.33B, based on a share price of $676.16 and 38.9M shares outstanding as of Jun 30, 2026.
Financials
Entrada Therapeutics reported revenue of $25.42M for fiscal 2025, down 87.94% from fiscal 2024.
Entrada Therapeutics reported a net loss of $143.75M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $25.42M | −87.9% | −$143.75M | −565.5% | −$3.47 | −$129.55M |
| FY2024ended Dec 31, 2024 | $210.78M | +63.4% | $65.63M | 31.1% | $1.68 | −$44.72M |
| FY2023ended Dec 31, 2023 | $129.01M | — | −$6.69M | −5.2% | −$0.20 | $134.19M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $898.00K | −$42.76M | −$1.01 |
| Q1 FY2026ended Mar 31, 2026 | $875.00K | −$39.72M | −$0.95 |
| Q4 FY2025ended Dec 31, 2025 | $1.30M | −$39.16M | −$0.95 |
| Q3 FY2025ended Sep 30, 2025 | $1.61M | −$44.13M | −$1.06 |
| Q2 FY2025ended Jun 30, 2025 | $1.95M | −$43.10M | −$1.04 |
| Q1 FY2025ended Mar 31, 2025 | $20.56M | −$17.35M | −$0.42 |
| Q4 FY2024ended Dec 31, 2024 | $37.40M | $1.13M | −$0.20 |
| Q3 FY2024ended Sep 30, 2024 | $19.57M | −$14.03M | −$0.35 |
Company profile
- Name
- Entrada Therapeutics, Inc.
- Ticker
- TRDA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- One Design Center Place, Suite 17-500, Boston, MA 02210
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001689375
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 10, 2026
- May 19, 2026
- May 7, 2026
- May 7, 2026
- Feb 26, 2026
- Feb 26, 2026
Frequently asked questions
What is Entrada Therapeutics's stock price?
Entrada Therapeutics (TRDA) closed at $676.16 on Oct 9, 2026, down 0.59% from the previous close of $680.14.
What is Entrada Therapeutics's market cap?
Entrada Therapeutics's market cap is $26.33B, based on a share price of $676.16 and 38.9M shares outstanding as of Jun 30, 2026.
How much revenue does Entrada Therapeutics make?
Entrada Therapeutics reported revenue of $25.42M for fiscal 2025, down 87.94% from fiscal 2024.
Does Entrada Therapeutics pay a dividend?
Entrada Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Entrada Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures